Genomatica Deploys Versant Open Access JDO, Endorses Versant-Proposed Eclipse JSR220-ORM Project
April 27 2005 - 9:30AM
PR Newswire (US)
Genomatica Deploys Versant Open Access JDO, Endorses
Versant-Proposed Eclipse JSR220-ORM Project Further Validation of
Versant's Open Source Strategy as Key Leveraging Component of
Overall Business Growth Goals FREMONT, Calif., April 27
/PRNewswire-FirstCall/ -- Versant Corporation (NASDAQ:VSNT), an
industry leader in specialized data management and data persistence
software, today announced that Genomatica, a leading computational
systems biology company, has deployed Versant Open Access JDO as a
key component of SimPheny, their software platform for systems
biology. Genomatica also endorses the proposed Eclipse JSR220-ORM
project, which will be led by Versant. Versant Open Access JDO
forms the initial code base of the proposed Eclipse JSR220-ORM
project, resulting in a standards-based, open source,
object-relational mapping (ORM) technology. Versant Open Access JDO
was Genomatica's top choice for object-relational mapping, beating
out several other standards-based solutions, and replacing an
existing non-standard, object-relational mapping product.
Genomatica also selected Versant to provide professional services
to help convert their application. Genomatica believes that the
Eclipse JSR220-ORM project is the best strategy for further
developing this technology and expanding its use. Object-relational
mapping is a software infrastructure that translates the data
formats used in the object-oriented languages preferred by
programmers to the relational structure of common databases.
SimPheny is a software platform that enables the development of
predictive computer models of organisms, from bacteria to humans.
With cellular metabolism at its core, SimPheny can build virtual
cells from their basic molecular components, and can simulate the
activity of the cell's complete reaction network. SimPheny delivers
a new range of efficiency to commercial biotechnology. "Versant
Open Access JDO gives us the ability to transparently support
complex mapping patterns and existing relational schema," explained
Evelyn Travnik, chief software designer at Genomatica. "After our
dissatisfaction with our previous object-relational mapping
solution, the prospect that the technology will be part of a
standards-based, open source solution in the Eclipse family is a
big positive for us. The Eclipse community is one of the leading
open source communities in Java, and brings a record of quality and
success. Versant's professional services where also very helpful in
getting our application converted to JSR220-ORM." "Genomatica is a
true leader in the emerging field of computational systems biology,
and we are pleased to support the vital functionality of
Genomatica's industry-leading solutions," said Robert Greene, vice
president of product strategy at Versant. "Genomatica's experience
with a non-standard ORM solution illustrates the benefits of
standards-based, open source technology like Eclipse JSR220-ORM."
"This business relationship with Genomatica is further validation
of our open source strategy, and an example of leveraging the
broader base of customer contact we expect as a result of this
strategy for business growth," said Nick Ordon, president and chief
executive officer of Versant. "Without the open source offering, it
would be very difficult to gain access to companies such as
Genomatica." About Genomatica Genomatica is a leading innovator of
biological modeling and simulation technologies transforming
biological research and the way microorganisms are engineered and
drugs are discovered. Using validated technology, Genomatica
delivers industry-leading solutions for the modeling and simulation
of metabolism. These solutions drive a powerful new paradigm,
called Model-Driven Metabolic Research, wherein computer models are
used to accelerate biological research and discovery across the
life sciences. Genomatica is advancing the frontiers of biological
discovery and the development of innovative products in medical and
industrial biotechnology, while streamlining existing product
development and enhancing the overall business efficiency of its
clients. Genomatica has developed SimPheny, a client-server
application that enables the development of predictive computer
models of organisms, from bacteria to humans. With cellular
metabolism at its core, SimPheny can build virtual cells from their
basic molecular components, and can simulate the activity of the
cell's complete reaction network. Genomatica is currently pursuing
commercial relationships with major bioprocessing, pharmaceutical
and biotechnology companies seeking to leverage the power of
model-driven systems biology for rapid biological discovery. For
more information, please visit us on our website at
http://www.genomatica.com/. About Versant Corporation Versant
Corporation is an industry leader in specialized data management
and open data access software. Using Versant's solutions, customers
cut hardware costs, speed and simplify development, significantly
reduce administration costs, and deliver products with a strong
competitive edge. Versant's solutions are deployed in a wide array
of industries including telecommunications, financial services,
transportation, manufacturing, and defense. With over 50,000
installations, Versant has been a highly reliable partner for over
15 years for Global 2000 companies such as British Airways, US
Government, Financial Times, IBM, and MCI. For more information,
call 510-789-1500 or visit http://www.versant.com/. Forward Looking
Statements Involve Risks and Uncertainties This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and is subject to the safe harbor created by
those sections. These forward-looking statements include, but are
not limited to, statements about the use of Versant's technology by
Genomatica, Versant's relationship with Eclipse, and the role and
placement of Versant's Open Access JDO product within the Eclipse
community. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve
risks and uncertainties, and there are important factors that could
cause our actual results to differ materially from those in the
forward looking statements. These factors include, without
limitation: that Versant may not achieve or maintain a leadership
role within the Eclipse community; that any such role obtained may
not remain intact in the future; possible changes in the direction
and emphasis within the Eclipse community; the possibility of
additional companies entering into this market segment; the
possible emergence of other standards-based, open source
technologies; the risk that others may not obtain similar results;
the possibility that Genomatica may discontinue the use of
Versant's technology; and the possibility that the business
resulting from the open source strategy may not match expectations.
The forward-looking statements included in this press release are
made only as of the date of this press release; the Company assumes
no obligation to publicly update any forward-looking statement.
Investors are cautioned not to place undue reliance on
forward-looking statements. Additional information concerning
factors that could cause results to differ can be found in the
Company's filings with the Securities and Exchange Commission,
including the Company's most recent Reports on Form 10-K and Form
10-Q made with the Securities and Exchange Commission. NOTE:
Versant is either a registered trademark or trademark of Versant
Corporation in the United States and/or other countries. All other
products are a registered trademark or trademark of their
respective company in the United States and/or other countries.
DATASOURCE: Versant Corporation CONTACT: public relations, Susan
Payne of O'Grady Communications, LLC, +1-919-929-5992, or ; or
investor relations, Scott Liolios of Liolios Group, Inc.,
+1-949-574-3860, or , both for Versant Web site:
http://www.versant.com/ Web site: http://www.genomatica.com/
Copyright
Versant (NASDAQ:VSNT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Versant (NASDAQ:VSNT)
Historical Stock Chart
From Jul 2023 to Jul 2024